Colorectal Cancer – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Colorectal cancer, also known as colon cancer, appears in the colon or the rectum and is the third leading cause of cancer that develops slowly over several years. It usually begins as a non-cancerous polyp, an abnormal growth of tissue that lines the colon. Colorectal cancer can manifest as sporadic (70%), familial clustering (20%), and inherited syndrome (10%). Several risk factors are associated with colon cancer, including age, environment, diets with high animal fat, obesity, cigarette smoking, heavy alcohol consumption, hereditary, and history of inflammatory bowel disease. The most common type of colon cancer found in patients diagnosed is adenocarcinoma. The adenoma-carcinoma sequence is the base for colorectal cancer development, with a build-up of genetic alteration. The gatekeeper (gene that regulates growth) pathway accounts for approximately 85% of sporadic colorectal cancers and is the mechanism of carcinogenesis in FAP patients. Mutation of the tumor-suppressor gene APC is a crucial step in this process. Several other tumor-suppressor genes (such as DCC DPC4/Smad4, nm32, and p53) and oncogenes (e.g., c-myc, c-neu,c-src, c-erb-2, and K-ras) are also involved. Other types of colon cancer are rare such as carcinoid tumors (start in hormone-producing cells in the intestines), gastrointestinal stromal tumors (soft tissue sarcoma), and lymphoma (related to autoimmune that can begin in the colon).

 

The incidence cases of Colorectal cancer range from 38 to 45 cases per 100,000 population in the USA.

 

The competitive landscape of Colorectal Cancer includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Colorectal Cancer across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Colorectal Cancer Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake, and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Colorectal Cancer – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          CMAB009 plus Irinotecan          Shanghai Zhangjiang Biotechnology Limited Company Phase 2

2          Regorafenib      Bayer   Phase 2

3          CBLB502          BioLab 612 LLC Phase 2

4          Aflibercept        Regeneron Pharmaceuticals      Phase 3

5          ALX148, Cetuximab and Pembrolizumab            Criterium, Inc.            Phase 2

6          DS-8201a         Daiichi Sankyo, Inc.       Phase 2

7          Anlotinib hydrochloride   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.           Phase 3

8          QL1203 Qilu Pharmaceutical Co., Ltd.     Phase 3

9          PM060184        PharmaMar       Phase 2

10        Magrolimab       Gilead Sciences            Phase 2

Continued.

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more